NKGen Biotech, Inc. (NKGN) News
Follow NKGen Biotech, Inc. (NKGN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
NKGen Biotech to Present on Troculeucel for Neurodegenerative Diseases at 4th Great Bay Cell and Gene Therapy Forum
SANTA ANA, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. OTC:NKGN (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autolog
NEWS | Sep 15, 2026, 12:11 PM UTC
L
NKGen Biotech to Present on Potential of Troculeucel in Neurodegenerative Diseases at Biologics Manufacturing Korea 2026
SANTA ANA, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. OTC:NKGN (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autolog
EQUITY | Sep 10, 2026, 12:11 PM UTC